Form 4: Moderna's Chief Legal Officer Shannon Thyme Klinger Reports Stock Transactions

Shannon Thyme Klinger, Moderna's Chief Legal Officer, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Summary

• On February 28, 2024, Shannon Thyme Klinger, Chief Legal Officer of Moderna, Inc., had restricted stock units convert into 1,315 shares of common stock.
• Also on February 28, 2024, Klinger acquired 9,227 shares.
• On February 29, 2024, Klinger sold 670 shares of common stock at a price of $94.572 per share to cover tax withholding obligations related to the vesting of restricted stock units.
• Following these transactions, Klinger directly owns 8,557 shares of Moderna common stock and 3,945 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, which is common for publicly traded companies like Moderna. It provides transparency into the trading activities of key personnel.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency in insider trading.
• Companies like Pfizer, BioNTech, and Johnson & Johnson also have similar insider transaction reporting requirements.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares, but it is primarily related to tax obligations of the reporting person.

Key Dates